Evaluating coronary blood flow and resistance in patients with angina
Official title: A Study of Pressure Waveform Analysis in Coronary Artery-II
Run by National Taiwan University Hospital Hsin-Chu Branch · NCT05672706 · Data updated 2026-11-12
This study is testing if using a special medication during heart tests can help people with angina understand their heart's blood flow and resistance better, while also checking how well these tests predict future heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | National Taiwan University Hospital Hsin-Chu Branch Academic / other |
| Locations | 1 site (Hsinchu) |
| Status | Recruiting |
| Started | January 4, 2023 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2027 |
| Registry record updated | January 5, 2023 |
| Trial ID | NCT05672706 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with angina who are undergoing evaluation for ischemic heart disease.
✕Probably not a fit
Patients with severe valvular heart disease, a history of asthma, or those with significantly low heart rates or blood pressure may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the feasibility of using intracoronary adenosine during evaluations of coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) in patients experiencing angina. It will measure the repeatability of CFR and IMR assessments while hyperemia is induced by adenosine and evaluate the correlation between coronary waveform signals and physiological ischemia as defined by fractional flow reserve (FFR) and CFR. Participants will undergo these assessments in a catheterization laboratory, followed by a three-year clinical event follow-up to determine the predictive value of FFR, CFR, and IMR on major adverse cardiovascular outcomes.
Why it matters
Potential benefit: If successful, this study could improve the understanding of coronary blood flow dynamics and enhance risk stratification for patients with ischemic heart disease.
How similar studies have gone: While this approach is observational and builds on existing methodologies, similar studies have shown promise in assessing coronary flow dynamics, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants with angina Exclusion Criteria: * Severe valvular heart disease * History of asthma * Heart rate less than 50 beats per minute * systolic blood pressure less than 90 mmHg
Where it's running
-
National Taiwan University Hospital Hsin-Chu branch
Hsinchu, Taiwan Recruiting
Study contacts
- Study coordinator: Chien-Boon Jong, MD
- Email: jgboon0407@gmail.com
- Phone: 035322140
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Outpatient Cardiac Telerehabilitation for Ischemic Heart Disease
This study tests whether an outpatient cardiac telerehabilitation program can be as safe and effective as conventional rehab for people with ischemic heart disease.
-
See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease
In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.
-
QFR-guided virtual stenting to optimize PCI before the procedure
We’re testing whether using QFR-based virtual stenting before PCI can improve heart-procedure outcomes compared with standard angiography planning in adults with coronary artery disease.
-
LONG NAGOMI PMCF: follow-up of the Ultimaster Nagomi stent in long coronary artery lesions
This project tests the Ultimaster Nagomi drug-eluting stent in adults undergoing PCI for long coronary lesions to collect real-world safety and effectiveness data.
-
Endocardial delivery of stem-cell derived heart cells to help severe heart failure
This study tests endocardial delivery of HS-001 cell sheets made from iPSC-derived cardiomyocytes in adults with severe heart failure and reduced ejection fraction to see if it is safe and may improve heart function over 26 weeks.
-
Deep learning to analyze and track echocardiograms
This project will test AI tools that help clinicians read echocardiograms and flag adults who may have genetic cardiomyopathy, ischemic heart disease, or cardiac amyloidosis to see if interpretation improves and diagnoses happen faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.